From 7034c2fe5d3ce6a9a2347e4fbb1a1a5b27e41b21 Mon Sep 17 00:00:00 2001 From: borja Date: Wed, 30 Oct 2024 15:37:52 +0100 Subject: [PATCH] Auto saved by Logseq --- pages/InCORNTD 2025___Application.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/pages/InCORNTD 2025___Application.md b/pages/InCORNTD 2025___Application.md index 8dc2d843..62c39bb6 100644 --- a/pages/InCORNTD 2025___Application.md +++ b/pages/InCORNTD 2025___Application.md @@ -3,7 +3,7 @@ - #+BEGIN_VERSE **Description**: The fixed-dose coformulation (FDC) of albendazole and ivermectin is the result of more than 10 years of innovations carried out by African and European organizations working through public-private partnerships. - This orodispersible, mango-flavoured tablet has already demonstrated safety and efficacy against soil-transmitted helminths in a 2022/2023 phase II/III pivotal trial. The results are already accepted for publication in Lancet Infectious Diseases and are currently being evaluated by the European Medicines Agency (EMA) under the EU-M4All procedure, and Ghana's FDA for registration. + This orodispersible, mango-flavoured tablet has already demonstrated safety and efficacy against soil-transmitted helminths in a 2022/2023 phase II/III pivotal trial. The results are already accepted for publication in Lancet Infectious Diseases and have been submitted to regulators. The FDC is being evaluated by the European Medicines Agency (EMA) under the EU-M4All procedure, and Ghana's FDA, with decisions anticipated in early 2025, which will be followed by WHO consideration for P The fixed-dose combination of albendazole and ivermectin provides a novel approach to mass drug administration campaigns that simplifies logistics while providing control abilities for more parasites. It allows for a more targeted approach #+END_VERSE